No abstract

frozen plasma transfusion, and graft implantation time, leading to 0e25 score points with an AUC of 0.7 in the new AKI-Predict-Score (Fig. 1). Three risk classes were identified: low-risk (0e10 points), intermediate-risk (11e20 points) and high-risk with >20 points. In addition, a score of >20 points correlated with impaired long-term graft survival and more postoperative complications assessed with the Comprehensive Complication Index. Conclusion:The AKI-Predict-Score is a new and reliable instrument to identify recipients at risk for severe post-transplant AKI. This score is readily available at end of the transplant procedure. This model offers therefore a great potential to decide which renal protective strategies might be implemented directly after liver transplant.

The aim of the present study was to assess the effects of gefitinib chemotherapy on the serum levels of miR-7 in patients with non-small cell lung cancer (NSCLC). A total of 126 patients were enrolled in the present study (stage I–II, n=54 and stage III–IV, n=72). Patients with stage I–II NSCLC underwent surgery in combination with gefitinib chemotherapy, whereas only gefitinib chemotherapy was administered to patients with stage III–IV disease. Serum levels of miR-7 before and after treatment were measured with quantitative polymerase chain reaction using fluorogenic probes, and miR-7 positivity and scoring in resected specimens were determined by immunohistochemistry. The number of miR-7-positive cases and the number of cases with higher miR-7 scores were significantly lower among patients with stage I–II NSCLC than those with stage III–IV disease. Additionally, serum levels of miR-7 before and after intervention were lower in stage I–II than in stage III–IV NSCLC cases. Serum levels of miR-7 after treatment were significantly lower than those before intervention in the two groups. The treatment success rate was significantly higher in miR-7-negative patients than in miR-7-positive patients in the two patient groups. Adverse event rates in miR-7-negative and -positive patients were comparable between the groups. Among those with stage III–IV NSCLC, the survival rate of miR-7-positive patients was significantly lower than that of miR-7-negative patients. Conversely, among those with I–II NSCLC, the progression-free survival and median survival time of miR-7-positive patients were significantly lower than those of miR-7-negative patients. Our findings suggest that serum and expression levels of miR-7 in the tissue were closely associated with tumor staging and the therapeutic effects of gefitinib in NSCLC.

No abstract

Aims: The aim of this study was to construct a nomogram that will predict the overall survival (OS) of hepatocellular carcinoma (HCC) patients after transarterial chemoembolization (TACE). Materials and Methods: Imaging data, clinical characteristics, and serum des-γ-carboxy prothrombin (DCP) levels of 93 HCC patients treated with TACE were collected. Lasso regression, random forest, and other methods were used to screen the OS-related variables and construct the Cox prognosis model. The model was visualized by nomogram, and the net benefit of the clinical decision was assessed by decision curve analysis (DCA). Results: It was found that DCP level after TACE was an important predictor of OS in HCC patients. The OS of the patients with lower serum DCP levels after TACE was significantly better than the group with higher levels (P = 0.003). The Cox prognostic model was constructed using four predictors including DCP reactivity (P = 0.001), modified Response Evaluation Criteria in Solid Tumors (mRECIST, P = 0.005), Child-Pugh class (P = 0.018), and portal vein thrombosis (P = 0.039). The C-index of the nomogram for OS of patients after TACE was 0.813. The clinical decision-making net benefits based on the nomogram were better than the decision-making based on the TNM stage system. Conclusion: DCP reactivity and mRECIST are the key predictors of prognosis in HCC patients that received TACE as their initial treatment. The nomogram constructed with these two indicators as the core could predict the OS of HCC patients after TACE and help in clinical decision-making.